Note 4 - Fair Value Measurements
|6 Months Ended|
Dec. 31, 2017
|Notes to Financial Statements|
|Fair Value, Measurement Inputs, Disclosure [Text Block]||
4.Fair Value Measurements:
Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt.
Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.
The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into
1inputs are quoted prices in active markets for identical assets or liabilities. Level
2inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
notactive, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level
3inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least
onesignificant model assumption or input is unobservable. Level
mayalso include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.
The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):
Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level
1assets. We value our Level
2assets using inputs that are based on market indices of similar assets within an active market.
All of our Level
2assets have maturity dates of less than
The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we
mayincur impairment charges for securities in our investment portfolio. We
mayalso incur changes to our contingent consideration liability as discussed below.
In connection with the Advanced Cell Diagnostics
(ACD) acquisition (fiscal
2017), as well as the Zephyrus and CyVek acquisitions (fiscal
2016), we are required to make contingent payments, subject to the entities achieving certain sales and revenue thresholds. The contingent consideration payments were up to
.0million related to the ACD, Zephyrus and CyVek acquisitions, respectively.
The fair value of the liabilities for the contingent payments recognized upon each acquisition as part of the purchase accounting opening balance sheet totaled
$37.0million for ACD,
$6.5million for Zephyrus and
$35.0million for CyVek) and was estimated by discounting to present value the probability-weighted contingent payments expected to be made. Assumptions used in these calculation units sold, expected revenue, discount rate and various probability factors. The ultimate settlement of contingent consideration could deviate from current estimates based on the actual results of these financial measures. This liability is considered to be a Level
3financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.
June 30, 2017the remaining conti
ngent consideration payments were up to
.0million related to the ACD, Zephyrus and CyVek acquisitions, respectively
. During the
firstquarter of fiscal
2018,a cash payment of
$35.0million was made towards to the contingent consideration liability relating to the CyVek acquisition. During the
secondquarter of fiscal
2018,the Company determined that certain sales and revenue thresholds were met for ACD. The Company expects to make a
$50.0million cash payment towards this liability in the
thirdquarter of fiscal
The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobser
vable inputs (Level
3) for the
December 31, 2017 (in thousands):
Fair value measurements of other financial instruments
– The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.
Cash and cash equivalents,
certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.
– The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility approximates fair value because our interest rate is variable and reflects current market rates.
The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.
Reference 1: http://www.xbrl.org/2003/role/presentationRef